Benzinga | May 28, 2021 07:52AM EDT

Cantor Fitzgerald Initiates Coverage On Harpoon Therapeutics with Overweight Rating, Announces Price Target of $40

Cantor Fitzgerald analyst Emma Nealon initiates coverage on Harpoon Therapeutics (NASDAQ:HARP) with a Overweight rating and announces Price Target of $40.